BlackRock Science & Technology Trust Launches $568M ATM Offering, Significant Dilution Expected

summarizeSummary

BlackRock Science & Technology Trust is launching an at-the-market offering to sell up to 12 million common shares, aiming to raise approximately $568 million in net proceeds. The offering price is at a discount to the fund's net asset value, leading to significant potential dilution for existing shareholders.

check_boxKey Events

• Launch of ATM Offering

  The Trust is initiating an at-the-market offering to sell up to 12,000,000 common shares, following a shelf registration filed on April 23, 2026.

• Substantial Capital Raise

  The offering is estimated to generate approximately $568 million in net proceeds, representing a significant capital infusion for the fund.

• Significant Share Dilution

  If all authorized shares are issued, existing shareholders face potential dilution of approximately 34.56%.

• Offering Priced Below NAV

  The shares are being offered at $47.83, which is a 7.77% discount to the fund's net asset value of $51.86 as of May 26, 2026.

auto_awesomeAnalysis

This 424B5 filing marks the active launch of an at-the-market (ATM) offering, allowing BlackRock Science & Technology Trust to sell up to 12 million common shares. While the previous N-2ASR filing on April 23, 2026, registered these shares, this prospectus supplement enables their actual sale. The offering aims to raise approximately $568 million in net proceeds, which is a substantial amount relative to the fund's market capitalization. However, the shares are being offered at $47.83, which is a discount to the fund's net asset value of $51.86 and below the current market price of $49.53. This pricing, combined with the potential issuance of 12 million new shares, represents significant dilution (approximately 34.56%) for existing shareholders. While raising capital is essential for a closed-end fund's growth and investment objectives, selling shares at a discount to NAV is generally viewed negatively as it reduces the per-share value for current investors. The fund is currently trading near its 52-week high, which provides a relatively strong market price for the capital raise, but the dilutive effect remains a key concern.